This is a PDF-only article. The first page of the PDF of this article appears below.
Log in using your username and password
Log in through your institution
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
PURCHASE SHORT TERM ACCESS
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Rodriguez, J. F., Melendez, M., Blanco, R., Rosario, O., Delgado, W., Davila, S., Casiano, D., Garcia, H., Mendez, O., Marrero, S., Costas, P., Gonzalez, C., Perez, C., Rodriguez, J. R., & Santana, J.(2004).
62 REDUCTION OF ZDV-TP AFTER 12 WEEKS OF TREATMENT WITH REBETRON® IN HIV-HCV CO-INFECTED PATIENTS..
Journal of Investigative Medicine,52(Suppl 2),
Accessed April 24, 2017.https://doi.org/10.1136/jim-52-suppl2-136.